In the future, the combined treatment strategy of inhibiting HKDC1 and anti-PD-1 /PD-L1 antibodies has shown significant anti-tumor effects, and may become an important direction of tumor immunotherapy in the future (Zhang et al., 2024). Here, HKDC1 is linked to neoplasm.